La vendita allo scoperto per Enovis dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Enovis. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Enovis (NYSE:ENOV) Azioni, Report sulle vendite allo scoperto

ENOVIS CORP

Enovis

Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.

Enovis Corp

Enova International Inc

Enovix Corp

Needham analyst Mike Matson reiterates Enovis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>) with a Buy and maintains $64 price target.

News

Price Target

Reiteration

Analyst Ratings

ENOV

Needham Reiterates Buy on Enovis, Maintains $64 Price Target

Enovis also reiterated its expectations for first quarter revenues to be in the range of $555 to $563 million and adjusted EBITDA in the range of $97 to $100 million.&nbsp;

Enovis Appoints Damien McDonald as CEO, Effective May 12 2025, Following Matt Trerotola's Retirement

Needham analyst Mike Matson maintains Enovis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>) with a Buy and lowers the price target from $65 to $64.

Needham Maintains Buy on Enovis, Lowers Price Target to $64

2025 Financial Outlook
Enovis also announced financial expectations for 2025. Revenue is expected to approximate $2.19-2.22 billion, which incorporates 6-6.5% organic revenue growth. Adjusted EBITDA is forecasted to be $405-415 million, which represents 60-70 basis points expansion year-over-year. Full-year adjusted earnings per share are expected to be in the range of $3.10-$3.25.

Earnings

Guidance

Health Care

General

Enovis Expects 2025 Revenue Of Approximately $2.19B-$2.22B, Compared To Consensus Of $2.22B, With Adjusted EPS Of $3.10-$3.25 Vs. $3.16 Est.

Management

Enovis Says Matt Trerotola Will Retire From His Position As CEO, The Board Is Actively Working With An Executive Search Firm To Identify The Company's Next CEO

Enovis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.92 by 6.52 percent. This is a 24.05 percent increase over earnings of $0.79 per share from the same period last year. The company reported quarterly sales of $560.98 million which beat the analyst consensus estimate of $555.15 million by 1.05 percent. This is a 23.29 percent increase over sales of $455.02 million the same period last year.

Enovis Q4 2024 Adj EPS $0.98 Beats $0.92 Estimate, Sales $560.98M Beat $555.15M Estimate

AAOI

ABEV

ACAD

ACMR

ADTN

ALEC

AMBA

AMBC

AMSF

ARDT

ARHS

ARIS

ARKO

ASTE

ATEC

AVDX

AVNS

BATRA

BATRK

BBSI

BLMN

BXSL

BYND

CAPL

CDNA

CERT

CLDT

CLPT

COCO

COMM

CORT

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRGY

CSAN

CTRI

DHIL

DMRC

DOLE

DORM

EBAY

ECPG

EHTH

ENIC

ERII

ESCA

ESTA

EVTC

FTAI

FWRD

GERN

GOGL

GSX Techedu Inc. American Depositary Shares

GOTU

GRBK

HCAT

HNST

IBTA

IMCR

Earnings Scheduled For February 26, 2025

Maplebear Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>), known for its online grocery delivery service Instacart, is trading higher following the announcement that it will join the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n42864159/maplebear-set-to-join-s-p-midcap-400-enovis-to-join-s-p-smallcap-600" rel="noreferrer noopener">S&amp;P MidCap 400 index</a>.
This change will see the company replace Enovis Corporation, with Enovis moving to the S&amp;P SmallCap 600. The index changes will take effect prior to the market&#8217;s opening on Tuesday, January 14.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, CART stock has gained over 92% in the past year. Investors can gain exposure to the stock via&nbsp;Advisor Managed Portfolios Trenchless Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVER#NYSE">RVER</a>).
In another development, Instacart has formed a nationwide partnership with retailer Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) to offer same-day delivery.
This collaboration introduces same-day delivery options for Ulta Beauty products through Instacart from over 1,400 Ulta locations nationwide.
Also Read: <a target="_blank" href="https://www.benzinga.com/economics/macro-economic-events/25/01/42878896/dollar-jumps-to-14-month-highs-30-year-yields-near-danger-zone-as-trump-m" rel="noreferrer noopener">Dollar Hits 14-Month High, 30-Year Yields Near Critical Threshold As Trump Reportedly Mulls Economic Emergency Tariffs</a>
The partnership also brings the integration of Ulta Beauty Rewards into the Instacart app, enabling Ulta members to earn rewards points on every Ulta purchase made via Instacart.
Per the press release, new customers can enjoy $10 off orders of $50 or more, valid until January 26.
Blake Wallace, Senior Director of Retail Partnerships at Instacart, expressed excitement about the partnership, noting it would offer customers more convenience and selection, particularly as many are focusing on wellness and self-care in the new year.
Jodi Williams, Vice President of eCommerce at Ulta Beauty, emphasized how the collaboration allows the brand to meet customers in even more places.
This new partnership with Instacart further expands Ulta Beauty&#8217;s reach, joining over 1,500 retailer banners already available on the Instacart platform, which spans categories from grocery to beauty and beyond.
Earlier this week, &nbsp;Ulta announced that&nbsp;Dave Kimbell retired as CEO and stepped down from the <a target="_blank" href="https://www.benzinga.com//node/42832069" rel="noreferrer noopener">company&#8217;s board.</a>
President and COO&nbsp;Kecia Steelman succeeded Kimbell as president and CEO, effective as of Monday. Steelman also joined the company&#8217;s board.
Ulta now expects comparable sales to &#8220;increase modestly.&#8221; Ulta also said it expects operating margin to be above the high-end of the company&#8217;s previous expected range of 11.6% to 12.4% of sales.
Ulta is scheduled to report fourth-quarter financial results on March 13.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, ULTA stock has lost over 14% in the past year. Investors can gain exposure to the stock via&nbsp;Neuberger Berman ETF Trust Neuberger Berman Next Generation Connected Consumer ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBCC#NYSE">NBCC</a>).
Price Action: CART shares are trading higher by 5.2% to $45.14 at last check Wednesday, while ULTA shares are trading lower by 3.10% to $415.01.
Read now:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42873182/us-private-businesses-add-122000-jobs-in-december-the-labor-market-downshifted-to-a-more-modest-pace-of-growth" target="_blank" rel="noreferrer noopener">US Private Businesses Add 122,000 Jobs In December: &#8216;Slowdown In Both Hiring And Pay Gains&#8217;</a></li>
</ul>
Image via Shutterstock.

Equities

Markets

Movers

ARCH

CART

Neuberger Berman ETF Trust Neuberger Berman Next Generation Connected Consumer ETF

NBCC

RVER

ULTA

Instacart Grows Stronger: S&P MidCap 400 Inclusion, Ulta Partnership Boosts Stock

Enovis To Replace Arch Resources In S&P SmallCap 600 Effective Prior To Opening Of Trading On January 14

Maplebear To Replace Enovis In S&P MidCap 400, Effective Prior To Opening Of Trading On January 14

Needham analyst Mike Matson reiterates Enovis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>) with a Buy and maintains $65 price target.

Needham Reiterates Buy on Enovis, Maintains $65 Price Target

Enovis Expects 2024 Adjusted EPS Of $2.75-$2.80 Versus Prior Expectations Of $2.62-$2.77 And Consensus Of $2.71

Enovis Narrowed Its Revenue Range And Adjusted  EBITDA  Expectations For 2024, With Sales Estimated At $2.1B Vs. $2.11B Est. And Adjusted EBITDA Of $373M-$378M Versus Prior Guidance Of $368M-$383M

Enovis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.62 by 17.74 percent. The company reported quarterly sales of $505.22 million which beat the analyst consensus estimate of $504.07 million by 0.23 percent. This is a 21.00 percent increase over sales of $417.52 million the same period last year.

Enovis Q3 2024 Adj EPS $0.73 Beats $0.62 Estimate, Sales $505.22M Beat $504.07M Estimate

JMP Securities initiated coverage on Enovis Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>), a medical technology company focusing on orthopedics.
The analyst adds that the company sells a broad portfolio of products, many of which were added via selective acquisitions (around 20 over the last 4.5 years). The analyst views M&amp;A as a core competency.
The company&#8217;s product offerings span large joint reconstruction implants, extremity solutions, and various prevention and recovery franchises.
These lines enable comprehensive care, addressing patient needs before, during, and after injury or trauma. This broad portfolio provides the scale to compete with major MedTech players and unlocks extensive opportunities for brand expansion.
Earlier this year, Enovis completed the acquisition of LimaCorporate S.p.A, a private global orthopedic company focused on restoring motion via a portfolio of implant solutions, for an enterprise value of approximately 800 million euros <a target="_blank" href="https://www.benzinga.com/markets/equities/23/09/34859649/big-moves-in-orthopedics-enovis-seals-800m-deal-to-acquire-limacorporate" rel="noreferrer noopener">(around $850 million)</a>.
This second-largest deal in the company&#8217;s history bodes well for the company.
Management noted that channel integration was 100% complete in the U.S. and 70% outside the U.S., revenues were tracking slightly better than original guidance, and cost synergies of over $40 million in year three remain intact, with $10-$15 million accruing this year.
In the second quarter, Enovis reported sales of $525 million, up 23% on a reported basis and 5% on a Comparable sales <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/g40213609/enovis-announces-second-quarter-2024-results" rel="noreferrer noopener">basis year-over-year</a>.
&#8220;We continue to execute against our plan for the year and are off to a great start integrating our transformational Lima acquisition,&#8221; said Matt Trerotola, CEO of Enovis.
The analyst views the LimaCorporate deal as largely derisked. Peak dis-synergy of ~$10 million occurred in the second quarter of 2024, which is now in the rearview mirror.
JMP analyst initiates with a Market Outperform rating and a <a target="_blank" href="https://www.benzinga.com/quote/ENOV/analyst-ratings" rel="noreferrer noopener">price target of $62</a>.
Despite a roughly 25% year-to-date decline in the stock and its current valuation at approximately 12x 2026 EPS estimates, JMP Securities says the market has yet to fully recognize the advantages of the acquisition and the progress made in its integration.
Given these factors, the analyst sees Enovis as undervalued compared to its mid-cap and orthopedic peers and deserving of a higher P/E multiple, especially with upcoming revenue and earnings growth catalysts.
Price Action: ENOV stock is down 2.02% at $40.02 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/24/10/41171072/amazon-accused-of-union-busting-after-drivers-unionize-nlrb-files-complaint" target="_blank" rel="noreferrer noopener">Amazon Accused of Union-Busting After Drivers Unionize, NLRB Files Complaint</a>.</li>
</ul>

Analyst Color

Initiation

Trading Ideas

Orthopedic Implant Player Enovis' M&A Strategy Core To Growth And Competitiveness, Analyst Says

Enovis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $58.75, a high estimate of $65.00, and a low estimate of $50.00. Experiencing a 10.54% decline, the current average is now lower than the previous average price target of $65.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1727956822_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Enovis among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$62.00</td>
<td>-</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$58.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$50.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$82.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Enovis. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Enovis compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Enovis's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Enovis's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ENOV/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Enovis analyst ratings.</a>
<h2>Get to Know Enovis Better</h2>
Enovis Corp is a medical technology company focused on developing clinically differentiated solutions that generate measurable patient outcomes and transform workflows by manufacturing and distributing high-quality medical devices with a broad use for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company conducts its operations through two operating segments: Prevention &amp; Recovery (P&amp;R) and Reconstructive (Recon). It generates the majority of revenue from the Prevention &amp; Recovery segment.
<h3>Financial Milestones: Enovis's Journey</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Enovis's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 22.56%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Enovis's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -3.55%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Enovis's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.57% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Enovis's ROA excels beyond industry benchmarks, reaching -0.34%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.43.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Latest Analyst Ratings For Enovis

JMP Securities analyst David Turkaly initiates coverage on Enovis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>) with a Market Outperform rating and announces Price Target of $62.

JMP Securities Initiates Coverage On Enovis with Market Outperform Rating, Announces Price Target of $62

Evercore ISI Group analyst Vijay Kumar maintains Enovis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>) with a Outperform and lowers the price target from $62 to $58.

Evercore ISI Group Maintains Outperform on Enovis, Lowers Price Target to $58

JP Morgan analyst Robbie Marcus maintains Enovis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>) with a Neutral and lowers the price target from $53 to $50.

JP Morgan Maintains Neutral on Enovis, Lowers Price Target to $50

Press Releases

Enovis to Participate in Upcoming Investor Conferences

Enovis to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Maplebear Set to Join S&P MidCap 400; Enovis to Join S&P SmallCap 600

Enovis™ Announces Leadership Change to International Surgical Business

Enovis to Host Fourth Quarter and Full Year 2024 Results Conference Call on February 26th

Comments

Enovis

Vendite allo scoperto

Enovis (NYSE:ENOV) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO